Focal segmental glomerulosclerosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of focal segmental glomerulosclerosis (FSGS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of FSGS for each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s FSGS forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of FSGS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following FSGS patient populations:
- Diagnosed incident cases of FSGS.
- Diagnosed prevalent cases of FSGS.
- Diagnosed incident cases of end-stage FSGS.
- Diagnosed prevalent cases of end-stage FSGS.
Note: Coverage may vary by country.
Table of contents
- Focal segmental glomerulosclerosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of focal segmental glomerulosclerosis)
- Diagnosed incident cases of focal segmental glomerulosclerosis
- Diagnosed prevalent cases of focal segmental glomerulosclerosis
- Diagnosed incident cases of end-stage focal segmental glomerulosclerosis
- Diagnosed prevalent cases of end-stage focal segmental glomerulosclerosis
- Risk / protective factors applied to disease forecast models
- Reference materials
Mariah Hamalainen, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Hamalainen earned her master’s degree in public health epidemiology from Florida International University, where she also worked as a graduate research assistant on an HIV testing and counseling study. She also completed two federally funded public health internships on data analysis and epidemiology. Her areas of interest are infectious diseases and women’s health.
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.